Kyverna TherapeuticsKYTX
About: Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases.
Employees: 112
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
175% more repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 12
2.67% more ownership
Funds ownership: 71.69% [Q1] → 74.36% (+2.67%) [Q2]
0% more funds holding in top 10
Funds holding in top 10: 4 [Q1] → 4 (+0) [Q2]
3% less first-time investments, than exits
New positions opened: 29 | Existing positions closed: 30
1% less funds holding
Funds holding: 89 [Q1] → 88 (-1) [Q2]
53% less call options, than puts
Call options by funds: $48K | Put options by funds: $102K
69% less capital invested
Capital invested by funds: $767M [Q1] → $241M (-$527M) [Q2]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
3 analyst ratings
UBS Trung Huynh 60% 1-year accuracy 3 / 5 met price target | 166%upside $13 | Buy Initiated | 10 Oct 2024 |
HC Wainwright & Co. Mitchell Kapoor 50% 1-year accuracy 66 / 131 met price target | 43%upside $7 | Neutral Reiterated | 19 Sept 2024 |
HC Wainwright & Co. Mitchell Kapoor 50% 1-year accuracy 66 / 131 met price target | 43%upside $7 | Neutral Maintained | 15 Aug 2024 |